Arkolith/Insider Trading/ETON/Form 4

Riedel Norbert G

DirectorEton Pharmaceuticals, Inc. (ETON) · full profile →Form 4 · filed Apr 22, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 21, 2026Option exercise(M)13K$7.31$91K48K
Apr 21, 2026Option exercise(M)20K$8.61$169K67K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 21, 2026Option exercise(M)13K—$00
Apr 21, 2026Option exercise(M)20K—$00

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-26-013041) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML